Resources

iBio’s new paper, “Quality Plant-Made mAbs with FastPharming®,” illustrates FastPharming’s ability to manufacture consistent, high-quality antibodies.

Monoclonal antibodies (mAbs) are a key class of biologic drugs. Their expression in alternative platforms, including plant-based systems, can provide a range of advantages. Two well-known mAbs, NISTmAb and rituximab, were produced in Nicotiana benthamiana and displayed increased homogeneity in their glycosylation pattern vs CHOmade analogs, while retaining similar pharmacokinetic properties. We believe these data support plant expression systems as promising alternatives for producing therapeutic mAbs for unmet medical needs.

This paper discusses ways developers across the biotherapeutics industry can overcome the high costs, long timelines, and low yield challenges of animal-based protein development. The included data was gathered over the course of a compelling project completed for Safi Biosolutions.

N-glycosylation is known to affect the biological activity of human therapeutics such as anti-cancer monoclonal antibodies, blood factors, or lysosomal enzymes. Over the last decade, several methods have been developed to enable the engineering of …

N-glycosylation has been shown to affect the pharmacokinetic properties of several classes of biologics, including monoclonal antibodies, blood factors, and lysosomal enzymes. In the last two decades, N-glycan engineering has been employed to achieve a …